{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T00:23:27Z","timestamp":1783556607416,"version":"3.55.0"},"reference-count":18,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,8,1]],"date-time":"2016-08-01T00:00:00Z","timestamp":1470009600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","thrombosisresearch.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Thrombosis Research"],"published-print":{"date-parts":[[2016,8]]},"DOI":"10.1016\/j.thromres.2016.05.023","type":"journal-article","created":{"date-parts":[[2016,5,23]],"date-time":"2016-05-23T22:23:17Z","timestamp":1464042197000},"page":"229-233","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Safety and efficacy of starting warfarin after two consecutive platelet count rises in heparin-induced thrombocytopenia"],"prefix":"10.1016","volume":"144","author":[{"given":"Lydia D.","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. Josh","family":"Roberts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5531-992X","authenticated-orcid":false,"given":"William E.","family":"Dager","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.thromres.2016.05.023_bb0005","series-title":"American College of Chest Physicians Evidence-Based Clinical Practice Guidelines","first-page":"e495s","article-title":"Treatment and prevention of heparin-induced thrombocytopenia: antithrombotic therapy and prevention of thrombosis","volume":"141","author":"Linkins","year":"2012"},{"key":"10.1016\/j.thromres.2016.05.023_bb0010","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/S0002-9343(96)00258-6","article-title":"A 14-year study of heparin-induced thrombocytopenia","volume":"101","author":"Warkentin","year":"1996","journal-title":"Am. J. Med."},{"key":"10.1016\/j.thromres.2016.05.023_bb0015","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1182\/asheducation-2009.1.225","article-title":"Heparin-induced thrombocytopenia: when a low platelet count is a mandate for anticoagulation","author":"Ortel","year":"2009","journal-title":"Hematology"},{"key":"10.1016\/j.thromres.2016.05.023_bb0020","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1136\/jnis.2010.002840","article-title":"Heparin induced thrombocytopenia: diagnosis and management","volume":"2","author":"Alaraj","year":"2010","journal-title":"J. Neurointervent. Surg."},{"key":"10.1016\/j.thromres.2016.05.023_bb0025","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1592\/phco.27.4.564","article-title":"Heparin-induced thrombocytopenia: treatment options and special considerations","volume":"27","author":"Dager","year":"2007","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.thromres.2016.05.023_bb0030","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1161\/01.CIR.103.14.1838","article-title":"Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia","volume":"103","author":"Lewis","year":"2001","journal-title":"Circulation"},{"key":"10.1016\/j.thromres.2016.05.023_bb0035","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1001\/archinte.163.15.1849","article-title":"Argatroban anticoagulation in patients with heparin-induced thrombocytopenia","volume":"163","author":"Lewis","year":"2003","journal-title":"Arch. Intern. Med."},{"key":"10.1016\/j.thromres.2016.05.023_bb0040","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1345\/aph.1A204","article-title":"Treatment of heparin-induced thrombocytopenia","volume":"36","author":"Dager","year":"2002","journal-title":"Ann. Pharmacother."},{"key":"10.1016\/j.thromres.2016.05.023_bb0045","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1161\/01.CIR.99.1.73","article-title":"Recombinant hirudin (lepirdin) provides safe and effective anticoagulation in patients with heparin-induced thrombocytopenia","volume":"99","author":"Greinacher","year":"1999","journal-title":"Circulation"},{"key":"10.1016\/j.thromres.2016.05.023_bb0050","doi-asserted-by":"crossref","first-page":"2389","DOI":"10.1111\/j.1538-7836.2011.04487.x","article-title":"Fondaparinux treatment of acute heparin-induced thrombocytopenia confirmed by the serotonin-release assay: a 30-month, 16-patient case series","volume":"9","author":"Warkentin","year":"2011","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.thromres.2016.05.023_bb0055","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1345\/aph.1Q177","article-title":"Bivalirudin dosing adjustments for reduced renal function with or without hemodialysis in the management of heparin-induced thrombocytopenia","volume":"45","author":"Tsu","year":"2011","journal-title":"Ann. Pharmacother."},{"key":"10.1016\/j.thromres.2016.05.023_bb0060","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1111\/j.1538-7836.2008.03025.x","article-title":"Quantitative interpretation of optical density measurements using PF4-dependent enzyme-immunoassays","volume":"6","author":"Warkentin","year":"2008","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.thromres.2016.05.023_bb0065","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1160\/TH14-11-0974","article-title":"Scoring systems for heparin-induced thrombocytopenia (HIT): whither now?","volume":"113","author":"Warkentin","year":"2015","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.thromres.2016.05.023_bb0070","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1002\/ajh.10181","article-title":"Venous limb gangrene during overlapping therapy with warfarin and a direct thrombin inhibitor for immune heparin-induced thrombocytopenia","volume":"71","author":"Smythe","year":"2002","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.thromres.2016.05.023_bb0075","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1111\/ejh.12179","article-title":"Fondaparinux-associated heparin-induced thrombocytopenia","volume":"91","author":"Bhatt","year":"2013","journal-title":"Eur. J. Haematol."},{"key":"10.1016\/j.thromres.2016.05.023_bb0080","series-title":"American College of Chest Physicians Evidence-Based Clinical Practice Guidelines","first-page":"340S","article-title":"Treatment and prevention of heparin-induced thrombocytopenia","volume":"133","author":"Warkentin","year":"2008"},{"key":"10.1016\/j.thromres.2016.05.023_bb0085","series-title":"Anticoagulation Therapy: a Point-of-Care Guide","first-page":"319","article-title":"Heparin induced thrombocytopenia","author":"Dager","year":"2011"},{"key":"10.1016\/j.thromres.2016.05.023_bb0090","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1517\/14740338.2013.823946","article-title":"Anticoagulant failure in coagulopathic patients: PTT confounding and other pitfalls","volume":"13","author":"Warkentin","year":"2013","journal-title":"Expert Opin. Drug Saf."}],"container-title":["Thrombosis Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384816303838?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384816303838?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,11]],"date-time":"2018-09-11T16:55:47Z","timestamp":1536684947000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049384816303838"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8]]},"references-count":18,"alternative-id":["S0049384816303838"],"URL":"https:\/\/doi.org\/10.1016\/j.thromres.2016.05.023","relation":{},"ISSN":["0049-3848"],"issn-type":[{"value":"0049-3848","type":"print"}],"subject":[],"published":{"date-parts":[[2016,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety and efficacy of starting warfarin after two consecutive platelet count rises in heparin-induced thrombocytopenia","name":"articletitle","label":"Article Title"},{"value":"Thrombosis Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.thromres.2016.05.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}